Perception of quality in municipal and private elderly care

Denna uppsats undersöker från ett brukarperspektiv om det finns några kvalitetsskillnader mellan den privata och kommunala äldreomsorgen inom Borås kommun. Undersökningen använder sig av sekundärdata, där Socialstyrelsen gjorde en enkätundersökning runt om i landets alla kommuner och som vi därefter sammanfattade alla svar utifrån det vi undersökte. I denna studie så samlades sekundärdata in för att sedan analyseras, för att sedan komma fram till hur kvaliteten är men även hur den skiljer sig åt på den kommunala samt privata äldreomsorgen. Kvaliteten som undersöks är bemötandet, tiden, tryggheten samt 4 äldreomsorgens olika områden som helhet. I studien finns även olika teorier kring kvaliteten samt hur man ska effektivisera arbetsplatserna så kvaliteterna höjs, så att man får fler nöjda brukare. Studien undersöker äldreomsorgen från tre olika sidor, vi undersökte hur kvaliteten är på ett äldreboende, särskilt boende samt hemtjänsten på både kommunal och privat äldreomsorg. Efter analysen av datamaterialet som används så fick vi fram ett resultat kring frågeställningen som löd, "Hur skiljer sig kvaliteten åt på kommunala kontra privat äldreomsorg?". Resultatet blev inte exakt som vi tänkte. Vår hypotes var att kommunal äldreomsorg skulle vara bättre på alla punkter med tanke på att privat äldreomsorg har mer med ett vinstdrivet tänk att göra. Slutresultatet var att det var ganska så jämnt, inom vissa områden var kvaliteten på kommunal bättre och i vissa fall så var kvaliteten inom privat bättre. Om man ser resultatet i helhet så var kommunal äldreomsorg bättre inom flera områden men inte med stora skillnader. Det vi kom fram till vara att kvaliteten på kommunal äldreomsorg är i sin helhet bättre än den privata äldreomsorgen. Vård och omsorg är ett brett ämne och vi rekommenderar att man forskar vidare kring det för att få en större samt djupare inblick i det hela.This study has been made from a user perspective to discuss and find out if there are any differences in quality between the municipal and private performers in elderly care in Borås municipality. The study was made through secondary data/information where the national board of health and welfare (Socialstyrelsen) made a survey in Sweden where the municipalities in Sweden participated, where we summarized the answers based upon our study. The valuable secondary data was collected and analyzed to learn how the quality is and how it differs from each other in private and municipal performers. The quality that is studied is the treatments, the time, and the feeling of safety but also the different parts that are included in the elderly care. The study also includes different theories that discuss the quality and how to make the workplaces more effective so that the quality could be improved so you have more satisfaction among the users. The study researches the elderly care from three different perspectives and how the quality is in a retirement home, special homes and home care in private and municipal performers. After analyzing the information and the data we got an answer on the question "How is the difference in municipal performance compared to private performers?" where our hypothesis was that the municipal performers would be better because the private ones are often profit-driven. The result was that they are pretty equal, in some areas the municipal was better than the private ones, but in some the private ones was better than the municipal. If we zoom out and look at the bigger picture, the municipal performers were better in more areas, but there wasn't that big of a difference, so if you compare the difference in performance between the municipal and private performers, in the whole big picture the municipal performers have better quality. Health and social care is a big subject and we recommend further study for better knowledge and differences that may come up

Perception of quality in municipal and private elderly care

Denna uppsats undersöker från ett brukarperspektiv om det finns några kvalitetsskillnader mellan den privata och kommunala äldreomsorgen inom Borås kommun. Undersökningen använder sig av sekundärdata, där Socialstyrelsen gjorde en enkätundersökning runt om i landets alla kommuner och som vi därefter sammanfattade alla svar utifrån det vi undersökte. I denna studie så samlades sekundärdata in för att sedan analyseras, för att sedan komma fram till hur kvaliteten är men även hur den skiljer sig åt på den kommunala samt privata äldreomsorgen. Kvaliteten som undersöks är bemötandet, tiden, tryggheten samt 4 äldreomsorgens olika områden som helhet. I studien finns även olika teorier kring kvaliteten samt hur man ska effektivisera arbetsplatserna så kvaliteterna höjs, så att man får fler nöjda brukare. Studien undersöker äldreomsorgen från tre olika sidor, vi undersökte hur kvaliteten är på ett äldreboende, särskilt boende samt hemtjänsten på både kommunal och privat äldreomsorg. Efter analysen av datamaterialet som används så fick vi fram ett resultat kring frågeställningen som löd, "Hur skiljer sig kvaliteten åt på kommunala kontra privat äldreomsorg?". Resultatet blev inte exakt som vi tänkte. Vår hypotes var att kommunal äldreomsorg skulle vara bättre på alla punkter med tanke på att privat äldreomsorg har mer med ett vinstdrivet tänk att göra. Slutresultatet var att det var ganska så jämnt, inom vissa områden var kvaliteten på kommunal bättre och i vissa fall så var kvaliteten inom privat bättre. Om man ser resultatet i helhet så var kommunal äldreomsorg bättre inom flera områden men inte med stora skillnader. Det vi kom fram till vara att kvaliteten på kommunal äldreomsorg är i sin helhet bättre än den privata äldreomsorgen. Vård och omsorg är ett brett ämne och vi rekommenderar att man forskar vidare kring det för att få en större samt djupare inblick i det hela.This study has been made from a user perspective to discuss and find out if there are any differences in quality between the municipal and private performers in elderly care in Borås municipality. The study was made through secondary data/information where the national board of health and welfare (Socialstyrelsen) made a survey in Sweden where the municipalities in Sweden participated, where we summarized the answers based upon our study. The valuable secondary data was collected and analyzed to learn how the quality is and how it differs from each other in private and municipal performers. The quality that is studied is the treatments, the time, and the feeling of safety but also the different parts that are included in the elderly care. The study also includes different theories that discuss the quality and how to make the workplaces more effective so that the quality could be improved so you have more satisfaction among the users. The study researches the elderly care from three different perspectives and how the quality is in a retirement home, special homes and home care in private and municipal performers. After analyzing the information and the data we got an answer on the question "How is the difference in municipal performance compared to private performers?" where our hypothesis was that the municipal performers would be better because the private ones are often profit-driven. The result was that they are pretty equal, in some areas the municipal was better than the private ones, but in some the private ones was better than the municipal. If we zoom out and look at the bigger picture, the municipal performers were better in more areas, but there wasn't that big of a difference, so if you compare the difference in performance between the municipal and private performers, in the whole big picture the municipal performers have better quality. Health and social care is a big subject and we recommend further study for better knowledge and differences that may come up

Discovery of Efficacious Pseudomonas aeruginosa-Targeted Siderophore-Conjugated Monocarbams by Application of a Semi-Mechanistic PK/PD Model

In order to identify new agents for the treatment of Pseudomonas aeruginosa infections to address the serious threat to society posed by the evolution of multi-drug resistant P. aeruginosa, we focused on the well established family of Beta-lactams antibiotics. There is evidence they are effective against the target pathogen and their resistance profiles and pharmacology are well established. To address the major resistance mechanisms to other Beta-lactam antibiotics we studied siderophore-conjugated monocarbams. This class of monocyclic Beta-lactams is stable to metallo Beta-lactamases and they have excellent P. aeruginosa activities due to their ability to exploit the iron uptake machinery of the Gram-negative bacteria. Our medicinal chemistry plan focused on identifying a molecule with optimal potency and physical properties and activity for in vivo efficacy. We examined modifications to the monocarbam linker, the siderophore, and the oxime portion of the molecules. Through these efforts we identified a series of pyrrolidinone-based monocarbams which have good P. aeruginosa cellular activity (P. aeruginosa MIC90 = 2 g/ml), excellent free fraction levels (> 20 % free) and good hydrolytic stability (t1/2 ≥ 100 h). In order to differentiate our compounds and enable prioritization for future in vivo studies, we developed a robust mechanistic PK/PD model which enables prediction of in vivo efficacy from in vitro data

Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferation.

A key challenge in the development of precision medicine is defining the phenotypic consequences of pharmacological modulation of specific target macromolecules. To address this issue, a variety of genetic, molecular and chemical tools can be used. All of these approaches can produce misleading results if the specificity of the tools is not well understood and the proper controls are not performed. In this paper we illustrate these general themes by providing detailed studies of small molecule inhibitors of the enzymatic activity of two members of the SMYD branch of the protein lysine methyltransferases, SMYD2 and SMYD3. We show that tool compounds as well as CRISPR/Cas9 fail to reproduce many of the cell proliferation findings associated with SMYD2 and SMYD3 inhibition previously obtained with RNAi based approaches and with early stage chemical probes

Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferation - Fig 1

<p><b>Chemical structures of SMYD2 (A) and SMYD3 (B) inhibitors</b>.</p

Anti-proliferative activity of SMYD2 inhibitors.

<p>(A) Correlation plots of (left) cellular methylation IC₅₀ as a function of biochemical IC₅₀ and (right) cell proliferation IC₅₀ as a function of cellular methylation IC₅₀ for SMYD2 inhibitors. (B) Western blot of BTF3 methylation showing dose dependent effects of EPZ032597. Data is representative of two independent experiments. (C) The effect of EPZ032597 on proliferation in a broad panel of cancer cell lines. (D) The effect LLY507 on proliferation of a broad panel of cancer cell lines. Values for C) and D) are the average of three biological replicates; error bars represent standard deviations (not readily visible on scale for all points). The 10 μM value represents the highest dose tested.</p

Biochemical and cellular potencies and physicochemical properties of SMYD2 and SMYD3 inhibitors used in this study.

<p>Biochemical and cellular potencies and physicochemical properties of SMYD2 and SMYD3 inhibitors used in this study.</p

Gene ablation techniques show no dependence on SMYD2 or SMYD3 for cancer cell proliferation.

<p>Waterfall plot representing LogP RSA scores for sgRNAs targeting A) SMYD2 and B) SMYD3. 313 cell lines were infected with a library of 6500 sgRNAs targeting 600 different genes. LogP RSA scores represent depletion of guides from an infected cell population. Each bar represents a different cell line. Bars are colored by cancer subtype. C) Percent confluency of Hep3B cells infected with CRISPR viruses containing CAS9 and sgRNAs targeting HBE-1, EZH2 (negative controls) or SMYD3. Cell density was evaluated using an Incucyte Zoom. Growth curves were initiated 24 days following virus infection and puromycin selection. Plotted data is the average of three biological replicates. Error bars represent standard deviation (not readily visible on scale). D) SMYD3 western blot of lysates derived from Hep3B cells infected with CAS9 and SMYD3 sgRNA. Parental Hep3Bs and Hep3Bs stably infected with HBE-1, EZH2 (negative controls) or SMYD3 were lysed and probed for SMYD3 levels by western. GAPDH levels were evaluated as a loading control.</p

Characterization of EPZ028862 as an inhibitor of SMYD3.

<p>A) Representative SMYD3 biochemical dose-response curve for EPZ028862 with a mean IC₅₀ value and standard deviation of 1.80 ± 0.06 nM from 2 experiments. B) Structure of EPZ028862 (cyan) with SMYD3 (green) and SAM (yellow) (PDB ID 5V37); water molecules are represented with red spheres. Electron density (2Fo−Fc, 1σ) for the compound is shown. Hydrogen bonds are indicated as dashed lines. C) Anti-proliferative activity of the SMYD3 inhibitor EPZ028862 across a broad panel of cancer cell lines in 2D culture (left) and in 3D culture (right). The 25 μM value represents the highest dose tested. Each value represents the mean of three replicates. Error bars represent the standard deviation (not readily visible on scale).</p